The aim of immunotherapy strategies is to leverage cells in the patient's own immune system to destroy tumor cells. Using a ...

Ironfist Therapeutics ("Ironfist"), a preclinical-stage company developing a nanomedicine radiopharmaceutical (Tamrada) that selectively targets tumor associated macrophages without a targeting ligand ...

New research from Indiana University School of Medicine scientists has revealed that a well-known cancer-fighting gene also ...

Reprogramming TAMs to an antitumorigenic state improves PD-1 blockade efficacy in metastatic ccRCC. High CD163-positive TAM density correlates with improved outcomes to nivolumab therapy. Spatial ...

SEPTEMBER 3, 2025, NEW YORK – Breast cancers frequently spread to the bone, establishing tumors that are largely impervious to treatment and are associated with poor patient prognoses. A deficiency in ...

Protumoral perivascular tumor-associated macrophages (PvTAMs) are a subset of TAMs that promote a chemotherapy-resistant tumor microenvironment (TME) through the expression of heme oxygenase-1 (HO-1).

Aging immune cells known as senescent macrophages are emerging as critical players in cancer progression. Rather than defending the body, these aged cells undergo profound functional shifts that ...

Macrophages are versatile immune cells, tasked with cleaning up pathogens and maintaining tissue health. But within the tumor microenvironment, they often shift into an M2-like state—one that ...

The clinical successes in immunotherapy have been staggering but remain partially unsatisfactory. Small molecules may play an important role individually or in combination with antibiotics in this ...